Professor | Weiqiang Lu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Weiqiang Lu
Contact Information	wqlu@bio.ecnu.edu.cn
Language ability	Chinese, English
Province	Shanghai

Upload Avatar (500 x 500)

Name

Weiqiang Lu

Contact Information

wqlu@bio.ecnu.edu.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	East China Normal University
Faculty	Life Sciences
Academic Background & Achievements	2004-2008: Bachelor's Degree from East China University of Science and Technology 2008-2013: PhD from East China University of Science and Technology
Work Experience	2013-2017: Assistant Researcher, Morning Scholar at East China Normal University, School of Life Sciences 2018-2022: Associate Researcher at East China Normal University, School of Life Sciences 2022-present: Researcher at East China Normal University, School of Life Sciences
Awards	2018: 22nd Chinese Pharmacological Society Young Pharmacologist Award 2019: 16th National Biochemistry and Molecular Pharmacology Conference Young Excellent Paper First Prize 2020: 'Internet+' College Students Innovation and Entrepreneurship Excellent Instructor 2021: 5th National Matrix Biology Conference Young Report Second Prize 2023: Shanghai Eastern Talent Program Young Project

University/Lab Affiliation and Title

East China Normal University

Faculty

Life Sciences

Academic Background & Achievements

2004-2008: Bachelor's Degree from East China University of Science and Technology
2008-2013: PhD from East China University of Science and Technology

Work Experience

2013-2017: Assistant Researcher, Morning Scholar at East China Normal University, School of Life Sciences
2018-2022: Associate Researcher at East China Normal University, School of Life Sciences
2022-present: Researcher at East China Normal University, School of Life Sciences

Awards

2018: 22nd Chinese Pharmacological Society Young Pharmacologist Award
2019: 16th National Biochemistry and Molecular Pharmacology Conference Young Excellent Paper First Prize
2020: 'Internet+' College Students Innovation and Entrepreneurship Excellent Instructor
2021: 5th National Matrix Biology Conference Young Report Second Prize
2023: Shanghai Eastern Talent Program Young Project

Areas of Focus	GPCR and tumor immune regulation Development of anti-tumor drugs targeting GPCR
Publications	PPIA dictates NRF2 stability to promote lung cancer progression, Weiqiang Lu, Jiayan Cui, Wanyan Wang, Qian Hu, Yun Xue, Xi Liu, Ting Gong, Yiping Lu, Hui Ma, Bo Feng, Qi Wang, Naixia, Zhang, Mingyao Liu, Ruth Nussinov, Feixiong Cheng, Hongbin Ji, Jin Huang Subtle Structural Changes across the Boundary between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-based Derivatives, Haojie Wang, Xinyu Yang, Yan Li, Shuyin Ze, Bo Feng, Mingyao Liu, Qiong Xie, Yonghui Wang, Weiqiang Lu, 2024 Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[d]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD), Ruoqing Zeng, Meimiao Fang, Ancheng Shen, Xiaolei Chai, Yumiao Zhao, Mingyao Liu, Lingfeng Zhu, Weiwei Rui, Bo Feng, Liang Hong, Chunyong Ding, Zilan Song, Weiqiang Lu, Ao Zhang, 2024 Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia, Hui Ma, Jiayan Cui, Zehui Liu, Wenqing Fang, Sisi Lu, Shuying Cao, Ji-an Chen, Lixue Lu, Qiong Xie, Yonghui Wang, Ying Huang, Kongfei Li, Hongyan Tong, Jin Huang, Weiqiang Lu, 2023 Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy, Chenyu Zhu, Shuyin Ze, Ronghui Zhou, Xinyu Yang, Haojie Wang, Xiaolei Chai, Meimiao Fang, Mingyao Liu, Yonghui Wang, Weiqiang Lu, Qiong Xie, 2023 Discovery of 2H-Indazole-3-carboxamide Derivatives as Novel Potent Prostanoid EP4 Receptor Antagonists for Colorectal Cancer Immunotherapy, Zhiyuan Cheng, Yijie Wang, Yao Zhang, Chan Zhang, Mengru Wang, Wei Wang, Hankun Zhang, Qiansen Zhang, Chunyong Ding, Deyan Wu, Linlin Yang, Mingyao Liu, Weiqiang Lu, 2023 Activation of orphan receptor GPR132 induces cell differentiation in acute myeloid leukemia, Chunyang Yi, Jiacheng He, Dan Huang, Yumiao Zhao, Chan Zhang, Xiyun Ye, Ying Huang, Ruth Nussinov, Junke Zheng, Mingyao Liu, Weiqiang Lu, 2022 Scaffold Hopping Strategy to Identify Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy, Wei Wang, Jiacheng He, Junjie Yang, Chan Zhang, Zhiyuan Cheng, Yao Zhang, Qiansen Zhang, Peili Wang, Shuowen Tang, Xin Wang, Mingyao Liu, Weiqiang Lu, Zhang Hankun, 2022 Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8 H)-one Derivatives as Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy, Fazhi Yu, Chenyu Zhu, Shuyin Ze, Haojie Wang, Xinyu Yang, Mingyao Liu, Qiong Xie, Weiqiang Lu, Yonghui Wang, 2022 From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis, Beier Jiang, Xingwu Jiang, Qiansen Zhang, Qiuwen Liang, Ziliang Qiu, Xiangbai Sun, Junjie Yang, Si Chen, Chunyang Yi, Xiaolei Chai, Mingyao Liu, Lifang Yu, Weiqiang Lu, HanKun Zhang, 2021 Reprogramming Immunosuppressive Myeloid Cells Facilitates Immunotherapy for Colorectal Cancer, Weiqiang Lu, Weiwei Yu, Jiacheng He, Wenjuan Liu, Junjie Yang, Xianhua Lin, Yuanjin Zhang, Xin Wang, Wenhao Jiang, Jian Luo, Qiansen Zhang, Huaiyu Yang, Shihong Peng, Zhengfang Yi, Shancheng Ren, Jing Chen, Stefan Siwko, Ruth Nussinov, Feixiong Cheng, Hankun Zhang, Mingyao Liu, 2021 Discovery and Characterization of 1 H-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy, JunJie Yang, WeiWei Yu, LongLong Hu, WenJuan Liu, XianHua Lin, Wei Wang, Qiansen Zhang, PeiLi Wang, ShuoWen Tang, Xin Wang, Mingyao Liu, Weiqiang Lu , HanKun Zhang, 2020 A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling, Yujie Huang, Jiansong Fang, Weiqiang Lu, Zihao Wang, Qi Wang, Yuan Hou, Xingwu Jiang, Ofer Reizes, Justin Lathia, Ruth Nussinov, Chris Eng, Feixiong Cheng*, 2019

Areas of Focus

GPCR and tumor immune regulation
Development of anti-tumor drugs targeting GPCR

Publications

PPIA dictates NRF2 stability to promote lung cancer progression, Weiqiang Lu*, Jiayan Cui, Wanyan Wang, Qian Hu, Yun Xue, Xi Liu, Ting Gong, Yiping Lu, Hui Ma, Bo Feng, Qi Wang, Naixia, Zhang, Mingyao Liu, Ruth Nussinov, Feixiong Cheng, Hongbin Ji, Jin Huang*
Subtle Structural Changes across the Boundary between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-based Derivatives, Haojie Wang, Xinyu Yang, Yan Li, Shuyin Ze, Bo Feng, Mingyao Liu, Qiong Xie*, Yonghui Wang*, Weiqiang Lu*, 2024
Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[d]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD), Ruoqing Zeng, Meimiao Fang, Ancheng Shen, Xiaolei Chai, Yumiao Zhao, Mingyao Liu, Lingfeng Zhu, Weiwei Rui, Bo Feng, Liang Hong, Chunyong Ding, Zilan Song*, Weiqiang Lu*, Ao Zhang*, 2024
Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia, Hui Ma, Jiayan Cui, Zehui Liu, Wenqing Fang, Sisi Lu, Shuying Cao, Ji-an Chen, Lixue Lu, Qiong Xie, Yonghui Wang, Ying Huang, Kongfei Li, Hongyan Tong, Jin Huang*, Weiqiang Lu*, 2023
Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy, Chenyu Zhu, Shuyin Ze, Ronghui Zhou, Xinyu Yang, Haojie Wang, Xiaolei Chai, Meimiao Fang, Mingyao Liu, Yonghui Wang*, Weiqiang Lu*, Qiong Xie*, 2023
Discovery of 2H-Indazole-3-carboxamide Derivatives as Novel Potent Prostanoid EP4 Receptor Antagonists for Colorectal Cancer Immunotherapy, Zhiyuan Cheng, Yijie Wang, Yao Zhang, Chan Zhang, Mengru Wang, Wei Wang, Hankun Zhang, Qiansen Zhang, Chunyong Ding, Deyan Wu, Linlin Yang, Mingyao Liu*, Weiqiang Lu*, 2023
Activation of orphan receptor GPR132 induces cell differentiation in acute myeloid leukemia, Chunyang Yi, Jiacheng He, Dan Huang, Yumiao Zhao, Chan Zhang, Xiyun Ye, Ying Huang, Ruth Nussinov, Junke Zheng*, Mingyao Liu*, Weiqiang Lu*, 2022
Scaffold Hopping Strategy to Identify Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy, Wei Wang, Jiacheng He, Junjie Yang, Chan Zhang, Zhiyuan Cheng, Yao Zhang, Qiansen Zhang, Peili Wang, Shuowen Tang, Xin Wang, Mingyao Liu*, Weiqiang Lu*, Zhang Hankun*, 2022
Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8 H)-one Derivatives as Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy, Fazhi Yu, Chenyu Zhu, Shuyin Ze, Haojie Wang, Xinyu Yang, Mingyao Liu, Qiong Xie*, Weiqiang Lu*, Yonghui Wang*, 2022
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis, Beier Jiang, Xingwu Jiang, Qiansen Zhang, Qiuwen Liang, Ziliang Qiu, Xiangbai Sun, Junjie Yang, Si Chen, Chunyang Yi, Xiaolei Chai, Mingyao Liu, Lifang Yu*, Weiqiang Lu*, HanKun Zhang*, 2021
Reprogramming Immunosuppressive Myeloid Cells Facilitates Immunotherapy for Colorectal Cancer, Weiqiang Lu*, Weiwei Yu, Jiacheng He, Wenjuan Liu, Junjie Yang, Xianhua Lin, Yuanjin Zhang, Xin Wang, Wenhao Jiang, Jian Luo, Qiansen Zhang, Huaiyu Yang, Shihong Peng, Zhengfang Yi, Shancheng Ren, Jing Chen, Stefan Siwko, Ruth Nussinov, Feixiong Cheng, Hankun Zhang*, Mingyao Liu*, 2021
Discovery and Characterization of 1 H-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy, JunJie Yang, WeiWei Yu, LongLong Hu, WenJuan Liu, XianHua Lin, Wei Wang, Qiansen Zhang, PeiLi Wang, ShuoWen Tang, Xin Wang, Mingyao Liu, Weiqiang Lu *, HanKun Zhang*, 2020
A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling, Yujie Huang, Jiansong Fang*, Weiqiang Lu*, Zihao Wang, Qi Wang, Yuan Hou, Xingwu Jiang, Ofer Reizes, Justin Lathia, Ruth Nussinov, Chris Eng, Feixiong Cheng*, 2019

Gpcr Tumor Immune Regulation Signaling Cell Signaling Molecular Mechanisms Drug Development Cancer Therapy Receptor Pharmacology Clinical Trials Molecular Targets Receptor Antagonists Medicinal Chemistry Tumor Environment Innovation

Yanping Xu - Tongji University

Zhang Jiamin - Tongji University

Zhang Mengjie - Tongji University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us